Who is sponsoring NCT02358694?

NCT02358694 is sponsored by Connecticut Children's Medical Center.

What drugs are being tested in NCT02358694?

Interventions in NCT02358694: Serum-Derived Bovine Immunoglobulin, Placebo.

What condition does NCT02358694 study?

NCT02358694 studies Diarrhea Predominant Irritable Bowel Syndrome.

Is NCT02358694 still recruiting?

NCT02358694 is currently completed. Last updated 18 February 2019.

Last reviewed 2019-02-18 · How we verify

NCT02358694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

Completed NA Last updated 18 February 2019

What this trial tests

NA trial testing Serum-Derived Bovine Immunoglobulin in Diarrhea Predominant Irritable Bowel Syndrome in 20 participants. Completed in 1 June 2015.

Timeline

15 June 2014

Primary endpoint
1 June 2015

1 June 2015

Quick facts

Lead sponsor	Connecticut Children's Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	20
Start date	15 June 2014
Primary completion	1 June 2015
Estimated completion	1 June 2015
Sites	1 location across United States

Drugs / interventions tested

Serum-Derived Bovine Immunoglobulin
Placebo

Conditions studied

Diarrhea Predominant Irritable Bowel Syndrome — all drugs for Diarrhea Predominant Irritable Bowel Syndrome →

Sponsor

Connecticut Children's Medical Center

Who can join

Adults 8 to 18, any sex, with Diarrhea Predominant Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted to see if serum-derived bovine immunoglobulin/protein isolate (SBI) is safe and well tolerated in pediatric patients with IBS-D. Main Hypothesis :Pediatric patients with IBS-D, who take SBI, will have no significant adverse events at 4 and 8 weeks and their quality of life will be better than the patients who receive placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Connecticut Children's Medical Center trials

Trials by the same sponsor.

NCT07224113 — Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD · recruiting
NCT06843330 — Accuracy of Lactate Meter in GSDIa · recruiting
NCT06982066 — Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention · NA · recruiting
NCT06101264 — Application of Virtual Reality in Post-Operative Recovery of a Pediatric Scoliosis Patient Population · NA · completed
NCT05874102 — The Effect of Body Position on Oropharyngeal Swallow Function in Infants · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02358694 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Connecticut Children's Medical Center
Last refreshed: 18 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02358694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing